Ongoing, recruitingTherapeutic exploratory (Phase II)Interventional

68Ga satoreotide trizoxetan PET/CT in patients with high grade neuroendocrine lung cancer

This research study is investigating a new imaging test called a 68Ga satoreotide trizoxetan PET/CT scan. It aims to see how effective this scan is at finding cancerous growths in people with specific kinds of high-grade neuroendocrine lung cancer, including small cell lung cancer (SCLC) and large cell neuroendocrine lung cancer (LCNEC). Doctors currently use scans like CT scans and sometimes other PET scans to find these cancer spots. This study wants to compare the new scan's ability to locate these lesions against existing methods. The overall goal is to understand if this new scan could help doctors get a clearer picture of where the cancer is in the body.

At a glance

Status

Ongoing, recruiting

Phase

Therapeutic exploratory (Phase II)

Sponsor

Rigshospitalet, Rigshospitalet

Enrolment target

Start

10 May 2023

large cell neuroendocrine lung cancer small cell lung cancer

What is this study about?

This study is focused on a new way to look for cancer in people who have specific types of lung cancer: small cell lung cancer (SCLC) and large cell neuroendocrine lung cancer (LCNEC). These are both types of 'high-grade neuroendocrine lung cancer', which means the cancer cells tend to grow and spread quite quickly.

The main aim is to test a special type of scan called a 68Ga satoreotide trizoxetan PET/CT scan. You might already know about regular CT scans or even other PET scans. This new scan uses a slightly different approach to try and highlight cancer cells. The researchers want to find out what percentage of patients with these lung cancers have at least one cancer spot that can be clearly seen using this new scan. Think of it like trying out a new pair of glasses to see if they help you spot specific things more clearly than your old ones.

Beyond just finding if the cancer is there, the study will also look at how many cancer spots the scan finds, where they are located, and how well this matches up with what other scans (like previous CT scans) have already shown. They will also measure how bright the cancer spots appear on the scan, which could give doctors more information about the cancer. By doing all this, the researchers hope to understand if this new scan could be a helpful tool for doctors when planning treatment for these types of lung cancer.

Key takeaways

This study is testing a new type of scan for specific lung cancers.
It aims to find out how well a PET/CT scan can locate cancer spots.
The research focuses on small cell and large cell neuroendocrine lung cancers.
All participants must be at least 18 years old, with no upper age limit.
Taking part helps doctors understand better ways to find cancer.

Who may be eligible?

To be considered for this study, you need to be at least 18 years old – there's no upper age limit. Both men and women can take part.

More specific details about your health and medical history, such as the exact type of lung cancer you have and any past or current treatments, will be discussed by the study team. These details are important to make sure the study is a good fit for you and that taking part would be safe.

It's important to understand that not everyone who meets these basic age and gender requirements will be able to join. The study team will review your full medical details to check if you meet all the necessary criteria for the research.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Am I 18 years old or older?
Have I been diagnosed with small cell lung cancer (SCLC) or large cell neuroendocrine lung cancer (LCNEC)?
Am I able to attend hospital appointments for scans?
Am I comfortable with receiving a new type of diagnostic scan?

Answer every question to see your result.

What does participation involve?

The detailed involvement for participants isn't provided here, but generally, taking part in a study like this would involve a number of visits to the hospital or clinic. You would likely undergo the new 68Ga satoreotide trizoxetan PET/CT scan, and this might be compared with your results from standard CT scans or other PET scans you've had. There would also be check-ups, and potentially blood tests to monitor your health. The total duration of your participation would depend on the study's design, but similar imaging studies often involve a few visits over a defined period, which could range from a few weeks to several months. You wouldn't be given new medication as part of the intervention itself, but rather a new type of diagnostic scan.

Potential risks and benefits

Patients might benefit from getting more detailed information about their cancer, which could help guide future treatment decisions, although this is not guaranteed for every participant. There is also the benefit of contributing to medical science, which could help others with similar conditions in the future. Potential risks might include exposure to a small amount of radiation from the PET/CT scan, and reactions to the substance injected for the scan, though these are usually mild. As with any medical procedure, there's always a small risk of unforeseen complications. Remember, you have the right to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Denmark

Common questions

What is a neuroendocrine lung cancer?

Neuroendocrine lung cancers are a group of lung cancers that start in special cells in the lungs called neuroendocrine cells. These cells have features of both nerve cells and hormone-producing cells.

What is a PET/CT scan?

A PET/CT scan is a type of imaging test that combines two different scans: a PET scan, which helps doctors see how your cells are working, and a CT scan, which takes detailed pictures of your body's structures. Together, they can give a more complete picture.

Will this new scan replace my current cancer treatments?

No, this study is about a diagnostic scan, not a treatment. It's looking to see if this new scan can give doctors more information about your cancer, which could then help them make better treatment plans for you.

What does 'malignant lesion' mean?

A 'malignant lesion' is another way of saying a cancerous spot or growth found in the body. The study aims to see how well the new scan can find these spots.

Will I have to pay to be part of this study?

Generally, expenses directly related to taking part in a clinical trial, such as the study scans and tests, are covered by the research study itself. It's always best to confirm this with the study team.